Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoHealth (GOCO) Research & Development (2019 - 2025)

GoHealth's Research & Development history spans 6 years, with the latest figure at -$50.7 million for Q3 2025.

  • For Q3 2025, Research & Development fell 211.29% year-over-year to -$50.7 million; the TTM value through Sep 2025 reached $39.3 million, down 76.94%, while the annual FY2024 figure was $41.0 million, 80.38% down from the prior year.
  • Research & Development for Q3 2025 was -$50.7 million at GoHealth, down from $26.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $106.9 million in Q3 2022 and bottomed at -$147.4 million in Q4 2021.
  • The 5-year median for Research & Development is $45.5 million (2023), against an average of $30.9 million.
  • The largest YoY upside for Research & Development was 985.49% in 2021 against a maximum downside of 217.72% in 2021.
  • A 5-year view of Research & Development shows it stood at -$147.4 million in 2021, then surged by 143.94% to $64.8 million in 2022, then grew by 16.13% to $75.2 million in 2023, then crashed by 83.88% to $12.1 million in 2024, then crashed by 518.13% to -$50.7 million in 2025.
  • Per Business Quant, the three most recent readings for GOCO's Research & Development are -$50.7 million (Q3 2025), $26.2 million (Q2 2025), and $51.7 million (Q1 2025).